

Title (en)
COMPOSITIONS AND METHODS FOR TREATING CELLULAR RESPONSE TO INJURY AND OTHER PROLIFERATING CELL DISORDERS
REGULATED BY HYALADHERIN AND HYALURONANS

Title (de)
ZUSAMMENSETZUNGEN UND VERFAHREN ZUR BEEINFLUSSUNG DER ZELLULÄREN ANTWORT AUF VERLETZUNGEN UND AUF
ANDERE VON HYALADHERIN UND HYALURONAN REGULIERTE ZELLPROLIFERATIONSSTÖRUNGEN

Title (fr)
COMPOSITIONS ET PROCEDES PERMETTANT DE TRAITER LA REPONSE CELLULAIRE AUX LESIONS ET D'AUTRES TROUBLES DE LA
PROLIFERATION CELLULAIRE REGULES PAR LES HYALADHERINES ET LES HYALURONANES

Publication
EP 1324765 A1 20030709 (EN)

Application
EP 00968173 A 20001005

Priority
IB 0001534 W 20001005

Abstract (en)
[origin: WO0228415A1] The present invention provides compositions and methods for treating a tissue disorder associated with a response-to-injury process or proliferating cells in a mammal. These tissue disorders are associated with a novel cellular phenotype designated as "transition cells" which are described herein. This cellular phenotype is characterized in having an activated *erk* kinase signaling activity, a stimulated AP-1 binding activity, and at least one characteristic selected from the group consisting of: (a) increased podosome formation, (b) increased flux of intracellular or extracellular hyaluronans or hyaladherins, (c) increased expression of a hyaladherin, (d) an inability to form focal adhesions, (e) increased metalloproteinase activity, and (f) increased expression of a hyaladherin. Example tissue disorders include fibrosis, inflammation, degeneration and invasive disorders such as occur in cancerous cells. The methods provided herein include administering to the mammal, an effective amount of a composition that alters the activity of transition molecules within a cell. Transition molecules are shown to be comprised of hyaladherins, hyaluronans and associated molecules that regulate the transitional phenotype. A novel cell culture comprising transition cells is also provided, as well as compositions comprising particular peptides, polypeptides, and antibodies that affect the transitional phenotype.

IPC 1-7
A61K 38/17; **C07K 14/705**; **C07K 7/08**

IPC 8 full level
A61K 38/17 (2006.01); **C07K 14/705** (2006.01); **C07K 16/28** (2006.01); **A61K 38/00** (2006.01)

CPC (source: EP)
A61P 17/02 (2017.12); **A61P 17/06** (2017.12); **A61P 19/02** (2017.12); **A61P 25/16** (2017.12); **A61P 25/28** (2017.12); **A61P 29/00** (2017.12); **A61P 35/00** (2017.12); **A61P 37/00** (2017.12); **C07K 14/705** (2013.01); **C07K 14/70596** (2013.01); **C07K 16/28** (2013.01); **A01K 2217/075** (2013.01); **A61K 38/00** (2013.01); **C07K 2317/34** (2013.01)

Citation (search report)
See references of WO 0228415A1

Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)
WO 0228415 A1 20020411; AU 7812200 A 20020415; CA 2448483 A1 20020411; EP 1324765 A1 20030709

DOCDB simple family (application)
IB 0001534 W 20001005; AU 7812200 A 20001005; CA 2448483 A 20001005; EP 00968173 A 20001005